{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Fannin Partners L.L.C., (\"Fannin\") of Houston, Texas.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/02/15/2019-02442.html","cfr_references":[],"citation":"84 FR 4492","comment_url":null,"comments_close_on":"2019-03-04","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 4, 2019 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2019-02442","effective_on":null,"end_page":4492,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/02/15/2019-02442.xml","html_url":"https://www.federalregister.gov/documents/2019/02/15/2019-02442/prospective-grant-of-an-exclusive-patent-license-treatment-of-acute-lymphoblastic-leukemia-t-cell","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-02442?publication_date=2019-02-15","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-02-15/2019-02442/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":116,"last_updated":"2026-06-24 22:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-02-15/pdf/2019-02442.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-02442.pdf?1550151929","publication_date":"2019-02-15","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/02/15/2019-02442.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T23:27:49Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":4492,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: “Treatment of Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof”","toc_doc":"Treatment of Acute Lymphoblastic Leukemia, T-cell Lymphoma, and Non-small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof","toc_subject":"Prospective Grant of an Exclusive Patent License:","topics":[],"type":"Notice","volume":84}